CFI
CFI (complement factor I, also known as FI, C3b-INA, C3bINA, KAF and IF) is a secreted trypsin-like serine protease that controls the complement cascade. It inactivates C3b and C4b, preventing unwanted complement activation on healthy cells. Browse Assay Genie's current range of CFI research reagents below, or read on for the biology behind the target.
CFI is a trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. It acts by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b, which inactivates both proteins. It also prevents assembly of the C3 and C5 convertase enzymes. These reactions depend on cofactors: factor H and C4BP in the fluid phase, and membrane cofactor protein (CD46) and CR1 on cell surfaces.
The cofactors on healthy cells allow CFI to degrade deposited C3b and so prevent undesired complement activation. On apoptotic cells or microbes the cofactors are absent, which leads to C3b-mediated complement activation and subsequent opsonisation. The CFI gene encodes a preproprotein that is cleaved into heavy and light chains. Disulfide bonds link them into a heterodimeric glycoprotein, which is secreted into the extracellular space. CFI belongs to the peptidase S1 family. HGNC places it among serine proteases, scavenger receptor cysteine rich domain containing proteins and complement system regulators and receptors.
CFI has also been known as I factor (complement). Defects in the gene cause complement factor I deficiency, an autosomal recessive disease associated with susceptibility to pyogenic infections. Mutations have also been linked to predisposition to atypical haemolytic uraemic syndrome, which is characterised by acute renal failure, microangiopathic haemolytic anaemia and thrombocytopenia. Primary glomerulonephritis with immune deposits and age-related macular degeneration are other associated conditions. Mouse and rat both carry a Cfi ortholog.
CFI controls all complement pathways by inactivating C3b and C4b, making it a central protein for studying how complement activity is restrained.
Mutations in the CFI gene are associated with predisposition to atypical haemolytic uraemic syndrome, marked by acute renal failure and thrombocytopenia.
Mutations of CFI are associated with age-related macular degeneration, linking complement regulation to this disease area.
CFI deficiency is autosomal recessive and associated with susceptibility to pyogenic infections, so the protein is relevant to innate immune defence research.
CFI is a trypsin-like serine protease that regulates all complement pathways. With cofactors such as factor H, C4BP, CD46 and CR1, it cleaves the alpha-chains of C3b and C4b and inactivates them. This protects healthy cells from undesired complement activation.
CFI stands for complement factor I. Aliases and previous symbols include FI, C3b-INA, C3bINA, KAF and IF, and the previous name is I factor (complement). The encoded preproprotein is cleaved into heavy and light chains joined by disulfide bonds.
Defects in CFI cause complement factor I deficiency. Mutations are also associated with atypical haemolytic uraemic syndrome, primary glomerulonephritis with immune deposits and age-related macular degeneration. Mouse and rat each have a Cfi ortholog; check the datasheet of any product for its validated reactivity.
Complement components, cofactors and regulators that act alongside CFI in controlling C3b and C4b.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P05156; product specifications from Assay Genie datasheets.